Oncolytic Adenovirus-Based Immunotherapy for Malignant Mesothelioma: Preclinical Advances and Future Perspectives

.blurhash-client-img { display: none !important; }

Open Access

|Jul 2025

Authors

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy

Department of Virology, National Institute of Public Health NIH – National Research Institute, Warsaw, Poland

Warsaw University of Technology, Warsaw, Poland

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy

Warsaw University of Technology, Warsaw, Poland

Department of Virology, National Institute of Public Health NIH – National Research Institute, Warsaw, Poland

Valo Therapeutics, Helsinki, Finland

DOI: https://doi.org/10.2478/am-2025-0004 | Journal eISSN: 2545-3149 | Journal ISSN: 0079-4252

Language: English, Polish

Page range: 46 - 50

Submitted on: Mar 23, 2025

Accepted on: May 30, 2025

Published on: Jul 8, 2025

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

Related subjects:

© 2025 Mariangela Garofalo, Monika Staniszewska, Stefano Salmaso, Paolo Caliceti, Lukasz Kuryk, published by Polish Society of Microbiologists
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.